[Form 4] C4 Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

C4 Therapeutics director Kenneth Carl Anderson received a stock option grant on June 18, 2025. The derivative security details include:

• Granted 35,500 stock options to purchase common stock
• Exercise price set at $1.44 per share
• Options expire on June 17, 2035
• Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting

The grant represents standard director compensation, with vesting contingent on continued board service. The filing was signed by attorney-in-fact Jolie M. Siegel on June 20, 2025. This Form 4 disclosure complies with SEC requirements for reporting changes in beneficial ownership by company insiders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderson Kenneth Carl

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.44	06/18/2025		A		35,500		(1)	06/17/2035	Common Stock	35,500	$0	35,500	D

Explanation of Responses:

1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Remarks:

	/s/ Jolie M. Siegel, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did C4 Therapeutics (CCCC) director Kenneth Anderson receive on June 18, 2025?

Kenneth Anderson received 35,500 stock options with an exercise price of $1.44 per share. These options were granted on June 18, 2025, and will expire on June 17, 2035.

When do Kenneth Anderson's CCCC stock options vest?

The stock options will vest and become exercisable in full upon the earlier of: (i) June 18, 2026, or (ii) C4 Therapeutics' next annual stockholders meeting, subject to Anderson's continued service as a Board member.

What is the exercise price of CCCC stock options granted to director Anderson in June 2025?

The stock options were granted with an exercise price of $1.44 per share.

How long does Kenneth Anderson have to exercise his CCCC stock options granted in June 2025?

The stock options have a 10-year term, with an expiration date of June 17, 2035.